Article Text

Download PDFPDF
Randomised controlled trial
Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding
  1. Jolanta M Siller-Matula1,
  2. Georg Delle-Karth1
  1. 1Department of Cardiology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to: Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Währinger Gürtel 18– 20, A-1090 Vienna, Austria; jolanta.siller-matula{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Antiplatelet therapy represents the mainstay of treatment for patients undergoing percutaneous coronary intervention.1 However, an increased risk for gastrointestinal bleeding is associated with use of aspirin and clopidogrel. To reduce the bleeding risk, proton pump inhibitors (PPIs) are prescribed in combination with platelet inhibitors, a strategy that is recommended by existing consensus guidelines2 though no randomised trial has proved this. Recently, a pharmacodynamic drug–drug interaction has been shown for clopidogrel and omeprazole but not for pantoprazole.3 4 Whether this interaction has an impact on patient outcomes has not been investigated in a randomised trial.


Clopidogrel and the Optimization of Gastrointestinal Events (COGENT) was a randomised, double-blind, placebo-controlled, phase III trial of the efficacy and safety of CGT-2168 (clopidogrel 75 mg and omeprazole 20 mg) compared with clopidogrel 75 mg alone. Patients were included in the trial if they were ≥21 years of age and treatment …

View Full Text


  • Competing interests None.